Prognostic Factors in Metastatic Melanoma
Author Information
Author(s): T. Muhonen, S. Pyrhonen, A. Laasonen, V.-M. Wasenius, S. Asko-Seljavaara, K. Franssila, L. Kangas
Primary Institution: Helsinki University Central Hospital
Hypothesis
The study investigates the prognostic value of flow cytometric parameters and tumor growth rate in metastatic melanoma.
Conclusion
The study proposes a prognostic scoring method that combines DNA flow cytometry results and tumor growth rate, indicating that patients with a higher score have poorer survival outcomes.
Supporting Evidence
- Patients with DNA diploid tumors survived a median of 16 months, while those with aneuploid tumors survived 27 months.
- Combining flow cytometry results and tumor growth rate provided a significant prognostic scoring method.
- Patients scoring above 0.75 had a median survival of 11 months compared to 30 months for those scoring below 0.75.
Takeaway
Doctors can use a new scoring system to predict how long patients with melanoma might live based on their tumor's growth and DNA characteristics.
Methodology
The study analyzed tumor samples from patients using DNA flow cytometry and assessed tumor growth rates under the mouse renal capsule.
Limitations
The study's findings may not apply to all melanoma patients due to variability in tumor characteristics and treatment responses.
Participant Demographics
The study included 117 patients, with 68 males and 49 females, aged 25 to 84.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% confidence 6-13
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website